Esa Ruokokoski
Overview
Explore the profile of Esa Ruokokoski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hovi P, Palmu A, Nieminen T, Artama M, Jokinen J, Ruokokoski E, et al.
PLoS One
. 2023 Feb;
18(2):e0282226.
PMID: 36827275
Safe vaccination is essential for mitigation of the COVID-19 pandemic. Two adenoviral vector vaccines, ChAdOx1 nCov-19 (AstraZeneca) and Ad26.COV2.S (Johnson&Johnson/Janssen) have shown to be effective and they are distributed globally,...
2.
Nieminen H, Lahdenkari M, Syrjanen R, Nohynek H, Ruokokoski E, Palmu A
Vaccine
. 2022 Sep;
40(42):6048-6054.
PMID: 36096971
Background: Live vaccines potentially have non-specific effects that protect against other infections than those the vaccines are targeted against. The national vaccination program (NVP) in Finland was changed on September...
3.
Rinta-Kokko H, Palmu A, Ruokokoski E, Nieminen H, Moreira M, Schuerman L, et al.
PLoS One
. 2022 Jan;
17(1):e0261750.
PMID: 34986178
Background: In the nation-wide double-blind cluster-randomised Finnish Invasive Pneumococcal disease trial (FinIP, ClinicalTrials.gov NCT00861380, NCT00839254), we assessed the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine...
4.
Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu A
Vaccine
. 2018 Aug;
36(39):5926-5933.
PMID: 30115524
Background: A bivalent HPV vaccine (Cervarix®; HPV2, GlaxoSmithKline) was introduced into the Finnish national vaccination programme (NVP) in November 2013 for girls aged 11-13 years with a catch-up for 14-15 ...
5.
Palmu A, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al.
Vaccine
. 2018 Mar;
36(14):1816-1822.
PMID: 29503110
Estimation of the full disease burden caused by Streptococcus pneumoniae is challenging due to the difficulties in assigning the aetiology especially in lower and upper respiratory infections. We estimated the...
6.
Okasha O, Rinta-Kokko H, Palmu A, Ruokokoski E, Jokinen J, Nuorti J
Thorax
. 2017 Oct;
73(3):262-269.
PMID: 28988217
Introduction: Limited data are available on population-level herd effects of infant 10-valent pneumococcal conjugate vaccine (PCV10) programmes on pneumonia. We assessed national trends in pneumococcal and all-cause pneumonia hospitalisations in...
7.
Kontio M, Palmu A, Syrjanen R, Lahdenkari M, Ruokokoski E, Davidkin I, et al.
J Infect Dis
. 2016 Feb;
213(12):2005-13.
PMID: 26908733
Background: Measles-mumps-rubella (MMR) vaccinations have been offered to Finnish children at 14-18 months and 6 years of age. In May 2011, the recommended age for the first vaccine dose was...
8.
Palmu A, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al.
Pediatr Infect Dis J
. 2015 Aug;
34(11):1230-5.
PMID: 26284652
Background: We evaluated the impact of the new pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10, GSK Vaccines) on tympanostomy tube placements (TTPs). Methods: Finnish Invasive Pneumococcal disease vaccine trial...
9.
Palmu A, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al.
Lancet Infect Dis
. 2013 Nov;
14(3):205-12.
PMID: 24287186
Background: Antimicrobial drugs are frequently prescribed to children for respiratory tract infections such as otitis, tonsillitis, sinusitis, and pneumonia. We assessed the effect of the ten-valent pneumococcal Haemophilus influenzae protein...
10.
Palmu A, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al.
Lancet
. 2012 Nov;
381(9862):214-22.
PMID: 23158882
Background: The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was designed to assess the effectiveness of a pneumococcal vaccine containing ten serotype-specific polysaccharides conjugated to Haemophilus influenzae protein D, tetanus...